CAMBRIDGE, Mass. — November 7, 2025 — Leads & Copy — Wave Life Sciences Ltd. (Nasdaq: WVE) announced its management team will participate in two healthcare conferences in November.
President and CEO Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025, at 10:00 a.m. ET.
Dr. Bolno will also participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Thursday, November 20, 2025, at 8:30 a.m. GMT / 3:30 a.m. ET. Additionally, he will be on the “Anti-Obesity Panel” at 9:00 a.m. GMT / 4:00 a.m. ET.
Live webcasts of the fireside chats can be accessed on the Wave Life Sciences website under “Investor Events” in the Investors section. Replays will be archived on the site for a limited time.
Wave Life Sciences (Nasdaq: WVE) focuses on developing RNA medicines. Its RNA medicines platform, PRISM®, utilizes modalities, chemistry innovation, and human genetics insights to treat rare and common disorders. The company’s RNA-targeting modalities include editing, splicing, RNA interference, and antisense silencing. Wave’s pipeline includes clinical programs for obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, with preclinical programs also in development.
Driven by the calling to “Reimagine Possible,” Wave Life Sciences is headquartered in Cambridge, MA. It can be followed on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
Source: Wave Life Sciences
